Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Lorvotuzumab Mertansine Well-Tolerated in Children at Adult Recommended Dose

October 23, 2020
By Hannah Slater
Article

However, though the CD56 target was confirmed to be expressed in the tumor types studied, the clinical efficacy of lorvotuzumab mertansine was limited.

A phase 2 study published in Cancer confirmed that lorvotuzumab mertansine (IMGN901) was well tolerated in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), or synovial sarcoma at the adult recommended phase 2 dose of 110 mg/m2.

Lorvotuzumab mertansine is an antibody drug conjugate that links a potent antimitotic (DM1) via a disulfide linker to CD56-targeting antibodies (lorvotuzumab). However, though the CD56 target was confirmed to be expressed in the tumor types studied, the clinical efficacy of lorvotuzumab mertansine was limited.

“Perhaps with alternative [antibody drug conjugate] components targeting CD56, the clinical impact of such therapy could be enhanced for patients with targeted tumors,” the authors wrote.

Patients included in the study were aged 12 months to 30 years and had relapsed after or progressed on standard therapy for their tumor type. Lorvotuzumab mertansine was administered at the adult recommended phase 2 dose of 110 mg/m2 per dose intravenously on days 1 and 8 of 21-day cycles. Notably, dexamethasone premedication at 4 mg/m2 per dose (maximum, 10 mg) the day before lorvotuzumab mertansine infusion was used.

Of note, the first 9 patients were enrolled at Children’s Oncology Group phase 1 and pilot consortium institutions for the monitoring of adverse events (AEs). Patients enrolled thereafter could be enrolled at any Children’s Oncology Group member institution in the US.

In total, 62 patients were enrolled in the phase 2 study. Thirty-five of the patients were male and the median age was 14.3 years (range, 2.8-29.9 years). Diagnoses included 17 patients with Wilms tumor, 17 with rhabdomyosarcoma, 12 with neuroblastoma, 10 with synovial sarcoma, 5 with MPNST, and 1 with pleuropulmonary blastoma.

Overall, 5 patients experienced 9 dose-limiting AEs, including hyperglycemia (n = 1), colonic fistula (n = 1) with perforation (n = 1), nausea (n = 1) with vomiting (n = 1), increased alanine aminotransferase in cycle 1 (n = 2), and increased alanine aminotransferase in cycle 2 (n = 1) with increased aspartate aminotransferase (n = 1). However, non-dose-limiting AEs of grade 3 or higher attributed to lorvotuzumab mertansine were rare.

“The adverse event profile of lorvotuzumab mertansine administered weekly for 2 of every 3 weeks at the adult maximum tolerated dose of 112 mg/m2 in pediatric solid tumor patients was similar to the profile for adults,” the authors noted.

The median values of the maximum concentration, half-life, and area under the curve from zero to infinity for DM1 were 0.87 μg/mL, 35 hours, and 27.9 μg/mL h, respectively.

On day 8, peripheral blood CD56+ leukocytes decreased by 71.9%. Importantly, 1 patient with rhabdomyosarcoma had a partial response, and 1 patient with synovial sarcoma achieved a delayed complete response.

“It is possible that the lack of efficacy in patients with solid tumors reflects limited delivery of the antimitotic payload to the cell, unfavorable delivery of the conjugate (due to either an inadequate dosing regimen or peritumoral factors), modifiers of CD56 binding/internalization such as CD56 isoforms with variable binding/internalization efficiencies, 30 altered intracellular processing of internalized lorvotuzumab mertansine, or tumor resistance to antimitotic agents such as DM1,” the authors explained.

Moving forward, the researchers recommended that future investigations focus on other factors involved in converting antibody drug conjugates targeting CD56 in relevant tumors in order to enhance tumor cytotoxicity.

Reference:

Geller JI, Pressey JG, Smith MA, et al. ADVL1522: A Phase 2 Study of Lorvotuzumab Mertansine (IMGN901) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma—A Children’s Oncology Group Study. Cancer. doi: 10.1002/cncr.33195

Recent Videos
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Related Content
Advertisement

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.


Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements

Brian Van Tine, MD, PhD
August 26th 2024
Podcast

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.


3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.


Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD
August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.


3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

ONCOLOGY Staff
February 19th 2025
Article

Experts discuss epithelioid sarcoma diagnosis, management, and targeted therapies, and highlight 3 things everyone should know about treatment.


The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation

Roman Fabbricatore
January 28th 2025
Article

The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Related Content
Advertisement

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma

Tim Cortese
May 29th 2025
Article

Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.


Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.

Afami-cel Approval May Open Gateway for Synovial Sarcoma Advancements

Brian Van Tine, MD, PhD
August 26th 2024
Podcast

Brian A. Van Tine, MD, PhD, discusses potential evolutions in the treatment landscape following the FDA approval of afami-cel in metastatic synovial sarcoma.


3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

3 Things You Should Know About Individualizing Care for Patients With Epithelioid Sarcoma

ONCOLOGY Staff
April 18th 2025
Article

Personalized therapeutic approaches and novel, targeted medicines can help patients with epithelial sarcoma attain better survival outcomes.


Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.

Sarcoma Awareness Month 2023 with Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD
August 1st 2023
Podcast

Brian Van Tine, MD, PhD, speaks about several agents and combination regimens that are currently under investigation in the sarcoma space, and potential next steps in research including immunotherapies and vaccine-based treatments.


3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

3 Things You Should Know About Identifying and Treating Epithelioid Sarcoma

ONCOLOGY Staff
February 19th 2025
Article

Experts discuss epithelioid sarcoma diagnosis, management, and targeted therapies, and highlight 3 things everyone should know about treatment.


The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Data Monitoring Committee OKs INVINCIBLE-3 Sarcoma Trial Continuation

Roman Fabbricatore
January 28th 2025
Article

The phase 3 INVINCIBLE-3 trial is evaluating INT230-6 vs standard of care in locally recurrent, inoperable, or metastatic soft tissue sarcoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.